Provention Bio, Inc. (NasdaqGS:PRVB) will look for acquisitions. Provention Bio announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. Provention Bio intends to use its net proceeds from the public offering for (i) pre-commercial activities, potential commercial activities, potential milestone or royalty payments, clinical development, and regulatory and manufacturing activities for PRV-031; (ii) development activities for PRV-015, PRV-101, and PRV-3279; (iii) the potential acquisition or in-licensing of other product candidates; and (iv) for other general corporate purposes.